# Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer

Source: https://onco.cc/trials/nct03739684/  
OnCo record `nct03739684` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Piflufolastat F-18 / Pylarify TruVu in Prostate cancer, run by Progenics Pharmaceuticals, Inc., completed.

## Summary

Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer is a phase 3 interventional study registered as NCT03739684 by Progenics Pharmaceuticals, Inc., with 208 participants recorded, started 2018-11-27 and reaching its primary completion in 2019-08-29. Interventions recorded: 18F-DCFPyL, PET/CT Imaging. Conditions recorded: Prostate Cancer, Prostate Adenocarcinoma, Prostate Cancer Recurrent, Prostate Cancer Metastatic.

Linked to the drug Piflufolastat F-18 / Pylarify TruVu because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03739684
- Phase: 3
- Setting: A Phase 3, Multi-Center, Open-Label Study to Assess the Diagnostic Performance and Clinical Impact of 18F-DCFPyL PET/CT Imaging Results in Men With Suspected Recurrence of Prostate Cancer
- Sponsor: Progenics Pharmaceuticals, Inc.
- Enrolled: 208

## Sources

- ClinicalTrials.gov NCT03739684: https://clinicaltrials.gov/study/NCT03739684

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Piflufolastat F-18 / Pylarify TruVu](https://onco.cc/drugs/pylarify/)
- companies: [Lantheus](https://onco.cc/companies/lantheus/)

---
JSON: https://onco.cc/api/v1/entities/nct03739684.json